Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444336 in Microscopic Colitis in Clinical Remission With Budesonide
NCT07156175Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- PEGylated Peptides, Interleukins
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in microscopic colitis (MC) comparing SAR444336 with Placebo (2 arms). Primary endpoint: Proportion of participants with sustained steroid-free clinical remission at 24 weeks. Started Oct 2025; status: recruiting.
02
Drugs
SAR444336
03
Conditions
microscopic colitis (MC)
Beyond the preview
Go deeper on NCT07156175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156175.